Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CS 1003

Drug Profile

CS 1003

Alternative Names: CS1003

Latest Information Update: 07 Feb 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CStone Pharmaceuticals
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Liver cancer
  • Phase I Lymphoma; Solid tumours

Most Recent Events

  • 13 Dec 2019 CStone Pharmaceuticals initiates enrolment in a phase III trial for Liver cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease) in China (NCT04194775)
  • 13 Dec 2019 Phase-III clinical trials in Liver cancer (Combination therapy, Late-stage disease, Inoperable/Unresectable, First-line therapy) in China (IV) (NCT04194775)
  • 11 Dec 2019 CStone Pharmaceuticals plans a phase III trial for Liver cancer (First-line therapy, Late-stage disease) in December 2019 (NCT04194775)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top